LEMTRADA was studied in two 2-year clinical trials against Rebif® (interferon beta-1a) 44 mcg. Patients were treated with LEMTRADA for 2 years and were then, if eligible, invited to continue in an Extension Study for an additional 4 years, for a total of 6 years in the studies.
patients in the 2-year study (Study 1) with 426 taking LEMTRADA, and 202 taking Rebif
of patients treated with LEMTRADA (387) entered the Study 1 Extension
of patients treated with LEMTRADA (332) that began Study 1 remained through Year 6